Cardurion Pharmaceuticals is a clinical-stage biotech focused on discovering and developing novel therapeutics for cardiovascular diseases. Its two lead programs are a first-in-class phosphodiesterase-9 (PDE9) inhibitor, CRD-750, and the first clinical-stage CaMKII inhibitor, CRD-4730. CRD-750 is being evaluated in two Phase 2 trials enrolling 640 patients across HFrEF and HFpEF populations, and CRD-4730 has an ongoing Phase 2 trial for catecholaminergic polymorphic ventricular tachycardia (CPVT). The company plans to expand cardiovascular indications for its portfolio, progress internal discovery programs, and acquire additional therapeutic assets. Proceeds from the recent financing will also be used to scale the team and build cardiovascular drug-development capabilities. Cardurion is headquartered in Burlington, Massachusetts, with discovery and research facilities in Shonan, Japan. Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing next-generation therapeutics for heart failure and other cardiovascular diseases by targeting cardiovascular signaling pathways. The company’s pipeline includes a PDE9 inhibitor and a CaMKII inhibitor program. Cardurion plans to advance its first-in-class PDE9 inhibitor into a major Phase 2 trial in heart failure and to initiate first-in-human studies for its CaMKII inhibitor across several cardiovascular indications. The recently announced financing will support thoughtful advancement of the pipeline, scaling of the team, and creation of an industry-leading platform. Cardurion was founded by physician-scientist Michael E. Mendelsohn and has facilities in Boston, Massachusetts and Shonan, Japan. Cardurion Pharmaceuticals is a biotechnology company developing novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Its lead clinical program is CRD-733, a novel phosphodiesterase-9 (PDE9) inhibitor in development for both forms of heart failure. The company also has two discovery programs focused on unique molecular targets for other cardiovascular diseases, including rare and more common arrhythmia disorders. Cardurion was founded by physician-scientist Michael E. Mendelsohn and pursues unique drug discovery and development programs in cardiovascular medicine. The company operates facilities in Boston, Massachusetts and Shonan, Japan. It has existing investor Takeda Pharmaceuticals and has consummated a private investment from Polaris Partners; the securities issued are unregistered and subject to applicable exemptions under U.S. securities laws.

Total raised

$560M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2024